Read the latest news from Health. Watch out for current health warnings. And find out how you can have your say on issues that affect you.
November is Lung Cancer Awareness Month and from 1 November, Keytruda® will be listed on the PBS for first-line treatment of people with metastatic non-small cell lung cancer.
The Australian Government will invest $52 million to protect Australian teenagers against meningococcal through a free national program for 14 to 19 year olds.
More than 400,000 Australians will now be able to access lifesaving scans for cancer, stroke, heart and other medical conditions with a $175 million investment from the Australian Government.
The Australian Government will invest $1 million from the Medical Research Future Fund to extend a rare cancers clinical trial.
The Pertussis Chapter, 4.12, of the 10th Edition of the Australian Immunisation Handbook has been updated and includes two changes to recommendations in the administration of pertussis-containing vaccine.
The shingles vaccine, Zostavax®, has been approved to be placed on the National Immunisation Program (NIP), to be provided free of charge from 1 November 2016 to people aged 70 years. There will also be a 5 year catch-up program for people aged 71 to 79 years.
Meningococcal B vaccine and clinical advice for immunisation providers regarding the use of Bexsero® (4CMenB). From 5 March 2014, the recombinant multicomponent meningococcal B vaccine Bexsero® (4CMenB) became available through purchase on the private market.
The Australian Technical Advisory Group on Immunisation is consulting with stakeholders on proposed changes to meningococcal and Haemophilus influenzae type B vaccination recommendations for inclusion in the Australian Immunisation Handbook.
Advice on the presence of natural rubber latex in the sheath covering the needle of the Fluad trivalent influenza vaccine. Anyone who has a severe allergy to latex should not receive Fluad.
The Zostavax® vaccine is now available nationally for immunisation providers for people aged 70 to 79 years under the National Immunisation Program (NIP).
The Australian Technical Advisory Group on Immunisation (ATAGI) has provided advice regarding alternatives during supply shortage of the adult formulations of hepatitis B vaccines.
The Australian Technical Advisory Group on Immunisation (ATAGI) has developed advice for immunisation providers regarding the administration of 2018 seasonal influenza vaccines.
Coverage rates amongst Australian children continue to improve with 5 year old children having the highest coverage rates in history. 94% of Australian 5 year olds and over 96% of Aboriginal and Torres Strait Islander 5 year olds are now fully vaccinated.
Australia's medicine and medical devices regulator, the Therapeutic Goods Administration (TGA), has decided to remove a number of mesh products whose sole use is the treatment of pelvic organ prolapse via transvaginal implantation from the Australian Register of Therapeutic Goods (ARTG).